Loading
A phase 2 trial of Antineoplastons in Glioma & glioblastoma, run by Burzynski Research Institute, completed.
Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme is a phase 2 interventional study registered as NCT00003456 by Burzynski Research Institute, with 40 participants recorded, started 1995-03-14 and reaching its primary completion in 2004-12-07. Interventions recorded: Antineoplaston therapy (Atengenal + Astugenal). Conditions recorded: Glioblastoma Multiforme of Brain.
Linked to the technology Antineoplastons because the registry's title names it ("antineoplastons") and Glioma & glioblastoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Antineoplastons (Burzynski clinic), Glioma & glioblastoma and the tag pipeline.
Shares Antineoplastons (Burzynski clinic) and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/